Predictive Technology Group, Inc. (PRED) Stock Analysis
DELISTED 2024
What happened to Predictive Technology Group, Inc. (PRED) stock?
Predictive Technology Group, Inc. (PRED) no longer trades on public markets. It was delisted in December 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Predictive Technology Group, Inc. (PRED) trades at $0.0001. Predictive Technology Group, Inc. focuses on developing and commercializing molecular diagnostics and therapeutics. Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for PRED: PRED does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PRED against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Predictive Technology Group, Inc. (PRED) Healthcare & Pipeline Overview
Predictive Technology Group, Inc. is a biotechnology company specializing in molecular diagnostics, therapeutics, and human cellular and tissue-based products, primarily focusing on fertility and regenerative medicine. Operating in the OTC market, the company aims to commercialize novel technologies and discoveries within the healthcare sector, facing competition and regulatory hurdles.
What Is the Investment Thesis for PRED?
Predictive Technology Group, Inc. presents a high-risk, high-reward investment profile. The company's focus on novel molecular diagnostics and regenerative medicine offers potential for significant growth, particularly in the fertility and cancer diagnostics markets. However, its negative profit margin of -351.4% and listing on the OTC market indicate substantial financial and operational challenges. Key value drivers include successful commercialization of its FertilityDX and ARTguide products, as well as the development of new diagnostic tools through its collaboration with Atrin Pharmaceuticals LLC. Growth catalysts include expanding its product offerings and securing regulatory approvals. Potential risks include limited access to capital, intense competition, and regulatory hurdles in the biotechnology sector. Investors should carefully consider these factors before investing.
Based on FMP financials and quantitative analysis
PRED Key Highlights
Operates in two segments: Human Cellular and Tissues Products (HCT/Ps) and Diagnostics and Therapeutics.
- Offers FertilityDX, a genetic testing service for couples experiencing infertility.
- Provides ARTguide, a genetic test for women experiencing infertility due to endometriosis and other genetic conditions.
- Develops regenerative medicine products, including AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte.
- Gross Margin of 15.8% indicates some ability to generate profit from revenue, but is relatively low.
Who Are PRED's Competitors?
PRED is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PRED's Key Strengths?
Proprietary diagnostic technologies.
- Focus on underserved markets (e.g., infertility).
- Collaboration agreement with Atrin Pharmaceuticals.
- Portfolio of regenerative medicine products.
What Are PRED's Weaknesses?
Negative profit margin.
- Limited financial resources.
- Reliance on OTC market for trading.
- Small number of employees.
What Could Drive PRED Stock Higher?
Potential regulatory approvals for new diagnostic or therapeutic products.
- Continued commercialization of FertilityDX and ARTguide products.
- Progress in the collaboration with Atrin Pharmaceuticals to develop cancer diagnostic tools.
What Are the Key Risks for PRED?
Financial-distress signal — its Altman Z-Score of -7.27 sits in the distress zone (elevated bankruptcy risk).
- Limited access to capital and financing.
- Intense competition from larger biotechnology companies.
- Stringent regulatory requirements and potential delays in product approvals.
- Negative profit margin and financial losses.
- Product liability risks associated with its products.
What Are the Growth Opportunities for PRED?
- Expansion into New Therapeutic Areas: Predictive Technology Group can expand its focus beyond fertility and regenerative medicine into other therapeutic areas, such as oncology and autoimmune diseases. The market for cancer diagnostics and therapeutics is estimated to reach $200 billion by 2028, offering significant growth potential. Success hinges on their collaboration with Atrin Pharmaceuticals and ability to develop novel diagnostic tools.
- Geographic Market Expansion: Currently focused in the US, Predictive Technology Group can expand its geographic reach into international markets, particularly in Europe and Asia. The global market for regenerative medicine is projected to reach $55 billion by 2027, with Asia being the fastest-growing region. This requires navigating international regulatory landscapes and establishing partnerships with local distributors.
- Strategic Partnerships and Acquisitions: Predictive Technology Group can pursue strategic partnerships or acquisitions to expand its product portfolio and market access. Partnering with larger pharmaceutical companies or acquiring smaller biotechnology firms can provide access to new technologies and distribution channels. The timeline for realizing these benefits depends on the availability of suitable targets and the successful integration of acquired assets.
- Development of Personalized Medicine Solutions: The increasing demand for personalized medicine offers a significant growth opportunity for Predictive Technology Group. By leveraging its expertise in molecular diagnostics, the company can develop personalized treatment plans tailored to individual patient needs.
- Increased Investment in Research and Development: Predictive Technology Group can increase its investment in research and development to accelerate the development of new products and technologies. This includes investing in preclinical and clinical studies to validate the efficacy and safety of its products. The timeline for realizing these benefits depends on the success of its R&D efforts and the ability to secure funding.
What Are PRED's Competitive Advantages?
- Proprietary diagnostic technologies.
- Established relationships with physicians and clinics.
- Intellectual property protection for its products and services.
- Collaboration agreements with pharmaceutical companies.
What Does PRED Do?
Predictive Technology Group, Inc., established in 2005 and headquartered in Salt Lake City, Utah, is a biotechnology company focused on developing and commercializing innovative molecular diagnostics, therapeutics, and human cellular and tissue-based products (HCT/Ps). The company operates through two segments: Human Cellular and Tissues Products (HCT/Ps), and Diagnostics and Therapeutics. Its product portfolio includes FertilityDX, a genetic testing service for couples experiencing infertility, and ARTguide, a genetic test designed for women facing infertility due to endometriosis and other genetic conditions. Additionally, Predictive Technology Group offers regenerative medicine products such as AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte, which are utilized in various regenerative medicine applications. The company also has a collaboration agreement with Atrin Pharmaceuticals LLC to develop molecular diagnostic tools aimed at improving cancer patient selection. Formerly known as Global Enterprises Group, Inc., the company rebranded as Predictive Technology Group, Inc. in July 2015, reflecting its strategic focus on predictive and personalized medicine. The company trades on the OTC market.
What Products and Services Does PRED Offer?
- Develops molecular diagnostic tools.
- Commercializes therapeutic products.
- Offers genetic testing services for couples experiencing infertility (FertilityDX).
- Provides genetic tests for women experiencing infertility due to endometriosis (ARTguide).
- Manufactures regenerative medicine products (AmnioCyte, AmnioCyte Plus, PolyCyte, CoreCyte).
- Collaborates with Atrin Pharmaceuticals to develop cancer diagnostic tools.
How Does PRED Make Money?
- Generates revenue through the sale of diagnostic testing services.
- Revenue from the sale of human cellular and tissue-based products (HCT/Ps).
- Partnerships and collaborations for development and commercialization of diagnostic tools.
- Potential for licensing agreements for its technologies.
What Industry Does PRED Operate In?
Predictive Technology Group, Inc. operates within the biotechnology industry, which is characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The market for molecular diagnostics and regenerative medicine is expanding, driven by increasing demand for personalized medicine and minimally invasive treatments. Competition is intense, with established players like NVTAQ (Invitae Corp) and emerging companies vying for market share. Predictive Technology Group's success depends on its ability to develop and commercialize innovative products that address unmet clinical needs and gain regulatory approval.
Who Are PRED's Key Customers?
- Couples experiencing infertility.
- Women experiencing infertility due to endometriosis and other genetic conditions.
- Physicians and clinics specializing in reproductive medicine.
- Hospitals and medical centers utilizing regenerative medicine products.
Company Profile
Predictive Technology Group, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Salt Lake City, US. The company is led by CEO Bradley C. Robinson. PRED has traded publicly since 2008.
Financial Health
Predictive Technology Group, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -7.27 places it in the distress zone, a signal of elevated financial risk.
PRED Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary diagnostic technologies.
- Focus on underserved markets (e.g., infertility).
- Collaboration agreement with Atrin Pharmaceuticals.
- Portfolio of regenerative medicine products.
Bear Case
- Negative profit margin.
- Limited financial resources.
- Reliance on OTC market for trading.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PRED Latest News
No recent news available for PRED.
Leadership: Bradley C. Robinson
CEO
Bradley C. Robinson serves as the CEO of Predictive Technology Group, Inc. His background includes experience in managing and leading companies, with a focus on strategic development and operational efficiency. He is responsible for overseeing the company's overall strategy, operations, and financial performance. His leadership is crucial for navigating the challenges of the biotechnology industry and driving the company's growth initiatives.
Track Record: Under Bradley C. Robinson's leadership, Predictive Technology Group has focused on developing and commercializing its diagnostic and therapeutic products. Key milestones include the expansion of its product portfolio and the establishment of strategic collaborations. His tenure has been marked by efforts to improve the company's financial performance and market position, despite operating in a competitive and highly regulated environment.
PRED OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Predictive Technology Group may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosures and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Higher price volatility.
- Potential for illiquidity.
- Increased risk of fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements.
- Research the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory filings.
- Evaluate the company's risk factors.
- Consult with a financial advisor.
- Understand the risks associated with OTC investing.
- Established business operations since 2005.
- Development of proprietary diagnostic technologies.
- Collaboration agreement with Atrin Pharmaceuticals.
- Focus on specific therapeutic areas (e.g., infertility).
- Presence of a CEO and management team.
What Investors Ask About Predictive Technology Group, Inc. (PRED) — Healthcare
What happened to Predictive Technology Group, Inc. (PRED) stock?
Predictive Technology Group, Inc. (PRED) no longer trades on public markets. It was delisted in December 2024. The figures below are historical and are not a current quote.
Can I still buy PRED shares?
No. PRED stopped trading on public markets in December 2024, so the shares are not available through a broker. Anything you see quoted for PRED elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PRED stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Predictive Technology Group, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Predictive Technology Group, Inc. do?
Predictive Technology Group, Inc. is a biotechnology company that develops and commercializes molecular diagnostic, therapeutic, and human cellular and tissue-based products (HCT/Ps). The company focuses on two main segments: Human Cellular and Tissues Products (HCT/Ps) and Diagnostics and Therapeutics.
What do analysts say about PRED stock?
As of March 16, 2026, there is no readily available analyst coverage or consensus on Predictive Technology Group, Inc. due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before making any investment decisions. Key valuation metrics, such as price-to-earnings ratio, are not meaningful due to the company's negative earnings.
What are the main risks for PRED?
The main risks for Predictive Technology Group, Inc. include its limited financial resources, negative profit margin, and reliance on the OTC market for trading. The company faces intense competition from larger biotechnology companies and is subject to stringent regulatory requirements. There are also product liability risks associated with its products. Investors should carefully consider these risks before investing in PRED.
What are the key growth opportunities for PRED in healthcare?
Predictive Technology Group, Inc. can expand into new therapeutic areas beyond fertility and regenerative medicine, such as oncology and autoimmune diseases. Geographic expansion into international markets, particularly in Europe and Asia, also presents a significant growth opportunity. Furthermore, the company can pursue strategic partnerships and acquisitions to expand its product portfolio and market access.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or delayed.
- AI analysis pending for PRED.